Points to Consider No.9 Lessons Learned from the COVID-19 Pandemic

Jan 2024
PDA Item Number

Premium Members: to claim your annual free technical document download, email [email protected] and indicate the document you wish to claim.

PDF Single User
Member Price
Nonmember Price
Government Price

As a result of the COVID-19 pandemic, many industries-the pharmaceutical included-went through a substantial disruption.Some of these disruptions included facility shutdowns, unprecedented supply chain challanges, worker availabitlity, and quality system limitations (e.g. physical signatures, investigations, document originals, risk assessments, audits.) For many pharmaceutical companies, challanges increased as they raced to provide a vaccine or a therapeutic treatment for COVID-19. Their manufacturing operations were changed over to accommodate the creation of the vaccine and, in order to get the vaccine to patients quickly, many logistical challanges arose.

This document provides lessons learned from the COVID-19 pandemic to pharmaceutical manufacturing. Areas covered include manufacturing, people, quality, regulatory and supply chain.


Table of Contents


I. Manufacturing

II. People

III. Quality

IV. Regulatory

V. Supply Chain

VI. Relevant Vendor and Supplier Resources

About the Authors